Myriad Genetics, Inc. $MYGN Shares Acquired by Inspire Investing LLC

Inspire Investing LLC increased its position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN) by 39.4% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 43,727 shares of the company’s stock after purchasing an additional 12,354 shares during the quarter. Inspire Investing LLC’s holdings in Myriad Genetics were worth $388,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of MYGN. Nuveen LLC acquired a new position in Myriad Genetics during the first quarter worth $10,437,000. Connor Clark & Lunn Investment Management Ltd. raised its holdings in Myriad Genetics by 67.8% during the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 921,911 shares of the company’s stock worth $8,177,000 after purchasing an additional 372,455 shares during the last quarter. AQR Capital Management LLC raised its holdings in Myriad Genetics by 278.9% during the first quarter. AQR Capital Management LLC now owns 433,392 shares of the company’s stock worth $3,844,000 after purchasing an additional 319,007 shares during the last quarter. Jane Street Group LLC raised its holdings in Myriad Genetics by 1,076.9% during the first quarter. Jane Street Group LLC now owns 213,826 shares of the company’s stock worth $1,897,000 after purchasing an additional 195,658 shares during the last quarter. Finally, Walleye Capital LLC acquired a new position in Myriad Genetics during the first quarter worth $1,655,000. 99.02% of the stock is owned by institutional investors and hedge funds.

Myriad Genetics Price Performance

Shares of NASDAQ:MYGN opened at $7.24 on Monday. The firm has a market capitalization of $673.65 million, a PE ratio of -1.69 and a beta of 1.93. The firm’s 50-day moving average is $5.58 and its two-hundred day moving average is $6.42. Myriad Genetics, Inc. has a 1 year low of $3.76 and a 1 year high of $29.30.

Wall Street Analyst Weigh In

Separately, Scotiabank cut Myriad Genetics from a “sector outperform” rating to a “sector perform” rating and cut their price target for the stock from $20.00 to $6.00 in a report on Wednesday, May 21st. Four equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $12.45.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.